Inozyme Pharma (INZY) Q4 2024 earnings summary

Executive summary

• Achieved key milestones in ENPP1 Deficiency program, including completion of ENERGY 3 pivotal trial enrollment and positive interim data from ENERGY 1 and Expanded Access Program evaluating INZ-701 in infants and young children.

• Strategic prioritization of ENPP1 Deficiency program, postponing other trials and implementing a 25% workforce reduction to extend cash runway into Q1 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $113.1 million as of December 31, 2024, down from $188.3 million at year-end 2023.

• R&D expenses increased to $83.2 million for 2024 from $54.8 million in 2023, mainly due to clinical development and manufacturing costs.

• G&A expenses remained flat at $20.8 million year-over-year.

• Net loss widened to $102.0 million ($1.62 per share) for 2024, compared to $71.2 million ($1.37 per share) in 2023.

Outlook and guidance

• Cash position and cost-saving measures expected to fund operations into the first quarter of 2026.

• Topline data from the ENERGY 3 pivotal trial anticipated in Q1 2026.